BRIEF-PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer

Reuters
13 Mar
BRIEF-PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer

March 13 (Reuters) - PDS Biotechnology Corp PDSB.O:

  • PDS BIOTECH ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR COMBINATION OF VERSAMUNE® MUC1 AND PDS01ADC TO TREAT METASTATIC COLORECTAL CANCER

Source text: ID:nGNX4FXJkf

Further company coverage: PDSB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10